[go: up one dir, main page]

IN2012DN00235A - - Google Patents

Info

Publication number
IN2012DN00235A
IN2012DN00235A IN235DEN2012A IN2012DN00235A IN 2012DN00235 A IN2012DN00235 A IN 2012DN00235A IN 235DEN2012 A IN235DEN2012 A IN 235DEN2012A IN 2012DN00235 A IN2012DN00235 A IN 2012DN00235A
Authority
IN
India
Prior art keywords
progression
prevention
delay
treatment
invention concerns
Prior art date
Application number
Inventor
Hans O Kalkman
Henari Mattes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN00235A publication Critical patent/IN2012DN00235A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of neuronal ceroid lipofuscinosis.
IN235DEN2012 2009-07-23 2010-07-23 IN2012DN00235A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22794009P 2009-07-23 2009-07-23
PCT/EP2010/060733 WO2011009951A1 (en) 2009-07-23 2010-07-23 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis

Publications (1)

Publication Number Publication Date
IN2012DN00235A true IN2012DN00235A (en) 2015-05-01

Family

ID=42671655

Family Applications (1)

Application Number Title Priority Date Filing Date
IN235DEN2012 IN2012DN00235A (en) 2009-07-23 2010-07-23

Country Status (12)

Country Link
US (1) US20120122903A1 (en)
EP (1) EP2456442A1 (en)
JP (1) JP2012533605A (en)
KR (1) KR20120052341A (en)
CN (1) CN102470137A (en)
AU (1) AU2010274921B2 (en)
BR (1) BR112012001258A2 (en)
CA (1) CA2768333A1 (en)
IN (1) IN2012DN00235A (en)
MX (1) MX2012000956A (en)
RU (1) RU2012106426A (en)
WO (1) WO2011009951A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5976011B2 (en) * 2011-04-05 2016-08-23 武田薬品工業株式会社 Sulfonamide derivatives and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2012533605A (en) 2012-12-27
WO2011009951A1 (en) 2011-01-27
MX2012000956A (en) 2012-02-28
AU2010274921B2 (en) 2014-08-14
AU2010274921A1 (en) 2012-02-02
BR112012001258A2 (en) 2016-02-10
CA2768333A1 (en) 2011-01-27
US20120122903A1 (en) 2012-05-17
CN102470137A (en) 2012-05-23
EP2456442A1 (en) 2012-05-30
RU2012106426A (en) 2013-08-27
KR20120052341A (en) 2012-05-23

Similar Documents

Publication Publication Date Title
IL242168A0 (en) Activin actriia antagonists and uses for the treatment or prevention of breast cancer
PL2349106T3 (en) System for the treatment of male sexual dysfunction
WO2011009890A3 (en) Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
GB201017345D0 (en) Receptor antagonists
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
BR112012009576A2 (en) mglur4 allosteric enhancer, compositions, and methods of treating neurological dysfunction
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
IN2012DN00572A (en)
FR2951637B1 (en) TABLE FOR MASSAGES OF EXTENDED OR SITUATED PERSONS.
MY150600A (en) Use of opioid antagonists for treating urinary retention
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
MX2013011490A (en) Pyridopyrazine derivatives and their use.
EA201170700A1 (en) TETRA-SUBSTITUTED PYRIDAZINES AS ANTAGONISTS OF THE HEDGEHOG WAY
IL206881A0 (en) Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy
EP2411042A4 (en) Tissue kallikrein for the treatment of pancreatic -cell dysfunction
CL2012001606A1 (en) Compounds derived from bicyclic thiazoles as allosteric modulators of mglur5 receptors; pharmaceutical composition comprising them; method of preparing the pharmaceutical composition; pharmaceutical combination; and use of the compound in the prevention, treatment or prophylaxis of neurological or psychiatric disorders.
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
TN2017000201A1 (en) Use of sigma receptor ligands in osteoarthritis
GB0917745D0 (en) Compositions for the prevention or treatment of migraine
IN2012DN00235A (en)
UA96574C2 (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
SG11202111525XA (en) Stable targeted integration
MX2014002693A (en) Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy.
SI2391366T1 (en) Substituted benzimidazoles for the treatment of astrocytomas
IL202506A0 (en) Neramexane for the treatment of nystagmus